Accessibility of cancer drugs in Switzerland
Time from approval to pricing decision between 2009 and 2018
Bibliographic Data
| ID | 21467701 |
|---|---|
| Authors | Kerstin Noëlle Vokinger (0000-0002-6997-7384, University of Zurich, corresponding author), Urs J Muehlematter (0000-0003-3423-4633, University of Zurich) |
| Year | 2020 |
| Volume | 124 |
| Issue | 3 |
| Pages | 261-267 |
| Publication date | 2020-03-01 |
| Peer Reviewed | Yes |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | Health Policy (JOURNAL) |
| Journal identifiers | ISSN: 0168-8510 • E-ISSN: 1872-6054 |
| Publisher | Elsevier BV (PUBLISHER) |
| DOI | 10.1016/j.healthpol.2019.12.006 |
| PMID | 31882156 |
| OpenAlex | W2995127773 |
| Language | EN |
| Citations received | 5 |
| References cited | 21 |
Cancer drugs · Drug · Drug approval · Family medicine · Health care · Political science · Reimbursement · Economic and Financial Impacts of Cancer · Health Systems, Economic Evaluations, Quality of Life · Law · Medicine · Pharmaceutical Economics and Policy · Psychology · Pharmacology
Do Drug Accessibility and OOP Burden Affect Health-Related Quality of Life of Patients With Chronic Diseases? — EQ-5D-5L Evaluation Evidence From Five Districts in China
Commentary
The influence of the national drug price negotiation policy reform on the medical expenses of patients in Xuzhou City
How value-based policy interventions influence price negotiations for new medicines
Early access to medicines with added therapeutic value
| Unique citing works | 5 |
|---|---|
| Citations per year | 0.83 |
| Citation span | 2020 - 2025 (6) |
| Citation velocity | recent |
| Highly cited | No |
| Citation types | Neutral: 5 |